REMARKS/ARGUMENTS

Applicants have fully considered the comments the Examiner presented in an Office Action mailed on December 15, 2006 and respectfully request reconsideration of claims 23-70. Claims 71-75 are withdrawn as noted by the Examiner.

The Examiner rejected the present claims under §112, first paragraph as not being enabling for treating a genetic disorder, condition or disease in a patient. The Examiner requested that the applicant provide evidence which is reasonably predictive that the claimed methods are effective for treating a genetic disorder, condition or disease in a patient.

Applicants submit a paper by *Carmona et al* (attached). This paper discusses a method for treating a disease, namely hepatitis B virus, by administering an effective amount of a compound according to the present invention, namely *N*1-cholesteryloxycarbonyl-3,7-diazononane-1,9-diamine (CDAN; the subject of present claim 30). Carmona discusses that administration of the compounds comprising CDAN demonstrates the ability to achieve efficient knockdown of hepatitis B virus to a level more effective than with a known drug. Thus, Carmona shows that it is reasonably predictive that the presently claimed methods are effective for treating diseases, including hepatitis B virus, in a patient.

The evidence now provided in the Carmona reference supports the evidence available in the application as filed. As previously discussed, the application as filed demonstrates the therapeutic potential of the compounds of the present invention based on CAT expression.

In view of the evidence in the specification, the state of the art and the newly filed paper by Carmona, Applicants submit that the present application enables the person skilled in the art to practice the claimed invention. Applicants therefore request that the rejection of lack of enablement be withdrawn.

Respectfully submitted,

FAY SHARPE LLP

Date: May 15, 2007

Joseph E. Waters, Reg. No. 50,427
1100 Superior Avenue, Seventh Floor
Cleveland, OH 44114-2579
Telephone: 216/861-5582

Attachments: Controlling Chronic HV Replication in Vivo With "Tailor-made" siRNA-ABC Nanoparticles